# Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

> **NCT06679465** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Saskatchewan** · enrollment: 10 (estimated)

## Conditions studied

- Asthma Bronchiale

## Interventions

- **DRUG:** Tiotropium (Spiriva®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06679465
- **Lead sponsor:** University of Saskatchewan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679465, "Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06679465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*